Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was up 13.6% during trading on Thursday . The stock traded as high as $8.25 and last traded at $8.3730. Approximately 420,534 shares changed hands during mid-day trading, an increase of 24% from the average daily volume of 337,961 shares. The stock had previously closed at $7.37.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on DRTS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Zacks Research raised shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 17th. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, March 10th. Citigroup boosted their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Finally, Piper Sandler reissued a "neutral" rating and set a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Alpha Tau Medical has an average rating of "Hold" and an average price target of $8.67.
Get Our Latest Research Report on Alpha Tau Medical
Alpha Tau Medical Price Performance
The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.45 and a current ratio of 7.45. The business's 50 day simple moving average is $7.34 and its 200-day simple moving average is $5.97. The stock has a market capitalization of $707.40 million, a price-to-earnings ratio of -15.74 and a beta of 1.04.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts anticipate that Alpha Tau Medical Ltd. will post -0.5 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Trifecta Capital Advisors LLC acquired a new position in shares of Alpha Tau Medical during the fourth quarter valued at approximately $48,000. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical during the third quarter valued at approximately $62,000. Bank of America Corp DE increased its stake in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after acquiring an additional 21,677 shares during the period. Wells Fargo & Company MN increased its stake in shares of Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after acquiring an additional 17,500 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Alpha Tau Medical during the third quarter valued at approximately $170,000. Institutional investors and hedge funds own 2.65% of the company's stock.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
